ONCAlert | 2017 San Antonio Breast Cancer Symposium

The Background and Future of Quizartinib for AML

Mark J. Levis, MD, PhD
Published Online:4:05 PM, Mon November 11, 2013
Mark J. Levis, MD, PhD, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses the background and future of quizartinib for FLT3-ITD acute myeloid leukemia at the 2013 Chemotherapy Foundation Symposium, which took place from November 6-8.

Clinical Pearls

  • Quizartinib could play a crucial role in the treatment of FLT3-ITD acute myeloid leukemia
  • Quizartinib has produced many clinically meaningful responses
  • The phase IIb study will analyze 30 mg and 60 mg doses
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.